Blair William & CO Gilead Sciences, Inc. Transaction History

Blair William & CO

$31.4 Billion
Q1 2024

A detailed history of Blair William & CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Blair William & CO holds 418,477 shares of GILD stock, worth $28.6 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

418,477

Previous 469,440 10.86%

Holding current value

$28.6 Million

Previous $38 Million 19.4%

% of portfolio

0.1%

Previous 0.13%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$71.58 - $87.29 $3.65 Million - $4.45 Million	-50,963 Reduced 10.86%	418,477 $30.7 Million
Q4 2023 Feb 12, 2024	SELL	$73.27 - $83.09 $158,263 - $179,474	-2,160 Reduced 0.46%	469,440 $38 Million
Q3 2023 Nov 09, 2023	SELL	$73.94 - $80.67 $984,141 - $1.07 Million	-13,310 Reduced 2.74%	471,600 $35.3 Million
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $218,224 - $248,915	-2,871 Reduced 0.59%	484,910 $37.4 Million
Q1 2023 May 12, 2023	SELL	$77.31 - $88.08 $2.48 Million - $2.83 Million	-32,133 Reduced 6.18%	487,781 $40.5 Million

Q4 2022 Feb 10, 2023	BUY	$62.32 - $89.47 $2.16 Million - $3.1 Million	34,625 Added 7.13%	519,914 $44.6 Million
Q3 2022 Nov 09, 2022	SELL	$59.54 - $68.01 $333,126 - $380,515	-5,595 Reduced 1.14%	485,289 $29.9 Million
Q2 2022 Aug 10, 2022	SELL	$57.72 - $65.01 $1.55 Million - $1.74 Million	-26,806 Reduced 5.18%	490,884 $30.3 Million
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $4.13 Million - $5.18 Million	-71,377 Reduced 12.12%	517,690 $30.8 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $842,401 - $956,141	12,984 Added 2.25%	589,067 $42.8 Million
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $2.97 Million - $3.2 Million	-43,866 Reduced 7.08%	576,083 $40.2 Million
Q2 2021 Aug 12, 2021	SELL	$63.47 - $69.35 $7 Million - $7.65 Million	-110,273 Reduced 15.1%	619,949 $42.7 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $1.34 Million - $1.53 Million	22,381 Added 3.16%	730,222 $47.2 Million
Q4 2020 Feb 09, 2021	SELL	$56.65 - $64.55 $6.36 Million - $7.25 Million	-112,322 Reduced 13.7%	707,841 $41.2 Million
Q3 2020 Nov 06, 2020	SELL	$62.1 - $78.08 $2.14 Million - $2.69 Million	-34,491 Reduced 4.04%	820,163 $51.8 Million
Q2 2020 Aug 12, 2020	BUY	$72.34 - $84.0 $3.65 Million - $4.23 Million	50,397 Added 6.27%	854,654 $65.8 Million
Q1 2020 May 11, 2020	SELL	$62.63 - $80.22 $8.05 Million - $10.3 Million	-128,459 Reduced 13.77%	804,257 $60.1 Million
Q4 2019 Feb 13, 2020	SELL	$61.62 - $67.78 $5.63 Million - $6.2 Million	-91,413 Reduced 8.93%	932,716 $60.6 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $5.52 Million - $6.1 Million	-88,370 Reduced 7.94%	1,024,129 $64.9 Million
Q2 2019 Aug 13, 2019	SELL	$61.87 - $69.38 $15.4 Million - $17.2 Million	-248,567 Reduced 18.26%	1,112,499 $75.2 Million
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $3.52 Million - $3.94 Million	56,270 Added 4.31%	1,361,066 $88.5 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $1.14 Million - $1.49 Million	-18,876 Reduced 1.43%	1,304,796 $81.6 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $3.05 Million - $3.38 Million	-42,825 Reduced 3.13%	1,323,672 $102 Million
Q2 2018 Aug 13, 2018	SELL	$64.88 - $75.68 $9.06 Million - $10.6 Million	-139,679 Reduced 9.27%	1,366,497 $96.8 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $3.42 Million - $4.17 Million	-46,971 Reduced 3.02%	1,506,176 $114 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $356,532 - $418,518	5,011 Added 0.32%	1,553,147 $111 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $112 Million - $132 Million	1,548,136	1,548,136 $125 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account